Scholarlink

Objectives <p>The global rise in type 2 diabetes mellitus (T2DM) poses challenges, particularly with the increasing burden of sarcopenia and poor glycemic control. Phase angle (PhA) is a promising biomarker for early detection and management of these conditions. This study aimed to evaluate PhA as an independent predictor of sarcopenia and glycemic control.</p> Methods <p>This cross-sectional study included older adults with T2DM hospitalized for diabetes education between April 2021 and March 2023. Measurements included PhA, muscle mass, body fat mass, grip strength, knee extension strength, physical function (Short Physical Performance Battery and 6-min walk distance), and glycemic control (fasting blood glucose and hemoglobin A1c [HbA1c]). Sarcopenia was defined as low muscle mass and physical function. Analyses included Pearson correlations, receiver operating characteristic curve analysis, and multivariate logistic regression.</p> Results <p>PhA was moderately correlated with muscle mass (<i>r</i> = 0.42, <i>p</i> &lt; 0.001), grip strength (<i>r</i> = 0.43, <i>p</i> &lt; 0.001), and body mass index (<i>r</i> = 0.27, <i>p</i> = 0.001), and inversely correlated with HbA1c (<i>r</i> = − 0.34, <i>p</i> &lt; 0.001) and age (<i>r</i> = − 0.26, <i>p</i> = 0.003). PhA showed a strong predictive ability for sarcopenia (AUC = 0.83, 95% CI: 0.76–0.90, <i>p</i> &lt; 0.001). Logistic regression indicated PhA as an independent predictor of sarcopenia (OR = 0.105, 95% CI: 0.031–0.353, <i>p</i> &lt; 0.001) and glycemic control (OR = 0.380, 95% CI: 0.201–0.719, <i>p</i> = 0.003).</p> Conclusions <p>PhA is a non-invasive, practical tool for predicting sarcopenia and monitoring glycemic control. Routine integration of PhA could identify high-risk patients and guide interventions. Future research should validate its application in diverse settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phase angle as an independent predictor of sarcopenia and glycemic control in older adults with type 2 diabetes: a cross-sectional observational study

  • 期刊论文

  • 发表日期：

    2025年3月15日

查看全文
  • Go Owari,
  • Kenichi Kono,
  • Takahiro Nonaka,
  • Yuto Watabe,
  • Yusuke Nishida,
  • Minoru Takemoto,
  • Wataru Kakuda

摘要

Objectives

The global rise in type 2 diabetes mellitus (T2DM) poses challenges, particularly with the increasing burden of sarcopenia and poor glycemic control. Phase angle (PhA) is a promising biomarker for early detection and management of these conditions. This study aimed to evaluate PhA as an independent predictor of sarcopenia and glycemic control.

Methods

This cross-sectional study included older adults with T2DM hospitalized for diabetes education between April 2021 and March 2023. Measurements included PhA, muscle mass, body fat mass, grip strength, knee extension strength, physical function (Short Physical Performance Battery and 6-min walk distance), and glycemic control (fasting blood glucose and hemoglobin A1c [HbA1c]). Sarcopenia was defined as low muscle mass and physical function. Analyses included Pearson correlations, receiver operating characteristic curve analysis, and multivariate logistic regression.

Results

PhA was moderately correlated with muscle mass (r = 0.42, p < 0.001), grip strength (r = 0.43, p < 0.001), and body mass index (r = 0.27, p = 0.001), and inversely correlated with HbA1c (r = − 0.34, p < 0.001) and age (r = − 0.26, p = 0.003). PhA showed a strong predictive ability for sarcopenia (AUC = 0.83, 95% CI: 0.76–0.90, p < 0.001). Logistic regression indicated PhA as an independent predictor of sarcopenia (OR = 0.105, 95% CI: 0.031–0.353, p < 0.001) and glycemic control (OR = 0.380, 95% CI: 0.201–0.719, p = 0.003).

Conclusions

PhA is a non-invasive, practical tool for predicting sarcopenia and monitoring glycemic control. Routine integration of PhA could identify high-risk patients and guide interventions. Future research should validate its application in diverse settings.